XIAMEN DAYUANJI ENTERPRISE MANAGEMENT CO.,LTD – Trademark Portfolio

Entity Type: 16

XIAMEN DAYUANJI ENTERPRISE MANAGEMENT CO.,LTD holds 1 U.S. trademark filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. Currently, 1 trademark is registered. Notable registered marks include MEWEUI. The owner is based in XIAMEN.

ROOM 611-6,NO.386 QISHAN ROAD,HULI

XIAMEN 361000 , CN

1 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

MEWEUI
MEWEUI
Registered 2020

Trademark Classifications

XIAMEN DAYUANJI ENTERPRISE MANAGEMENT CO.,LTD's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does XIAMEN DAYUANJI ENTERPRISE MANAGEMENT CO.,LTD have?

XIAMEN DAYUANJI ENTERPRISE MANAGEMENT CO.,LTD has 1 U.S. trademark filed with the USPTO. Of these, 1 registered.

What trademark classes does XIAMEN DAYUANJI ENTERPRISE MANAGEMENT CO.,LTD file in?

XIAMEN DAYUANJI ENTERPRISE MANAGEMENT CO.,LTD files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are XIAMEN DAYUANJI ENTERPRISE MANAGEMENT CO.,LTD's most well-known trademarks?

XIAMEN DAYUANJI ENTERPRISE MANAGEMENT CO.,LTD's registered trademark portfolio includes well-known marks such as MEWEUI. These are among 1 currently registered trademark in the portfolio.

What is XIAMEN DAYUANJI ENTERPRISE MANAGEMENT CO.,LTD's trademark registration success rate?

XIAMEN DAYUANJI ENTERPRISE MANAGEMENT CO.,LTD has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 0 applications are pending review.